MariMed
Stock Forecast, Prediction & Price Target
MariMed Financial Estimates
MariMed Revenue Estimates
MariMed EBITDA Estimates
MariMed Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $121.46M N/A | $134.01M 10.32% | $148.59M 10.88% | Avg: $178.1M Low: $171.46M High: $184.73M avg. 19.85% | Avg: $248.3M Low: $239.05M High: $257.54M avg. 39.41% | ||
Net Income
% change YoY
| $7.22M N/A | $13.46M 86.40% | $-16.03M -219.03% | Avg: $3.63M Low: $3.45M High: $3.80M avg. 122.66% | Avg: $10.90M Low: $10.37M High: $11.42M avg. 200% | ||
EBITDA
% change YoY
| $31.92M N/A | $30.62M -4.07% | $11.16M -63.55% | Avg: $19.96M Low: $19.22M High: $20.70M avg. 78.85% | Avg: $27.83M Low: $26.79M High: $28.87M avg. 39.41% | ||
EPS
% change YoY
| $0.02 N/A | $0.04 80.54% | -$0.04 -210.52% | Avg: $0.01 Low: $0.01 High: $0.01 avg. 122.67% | Avg: $0.03 Low: $0.03 High: $0.03 avg. 199.99% | ||
Operating Expenses
% change YoY
| $37.53M N/A | $38.87M 3.56% | $51.53M 32.56% | Avg: $49.40M Low: $47.56M High: $51.24M avg. -4.13% | Avg: $68.87M Low: $66.31M High: $71.44M avg. 39.41% | ||
FAQ
What is MariMed stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 161.33% in 2025-2026.
We have gathered data from 1 analysts. Their low estimate is 3.45M, average is 3.63M and high is 3.80M.
What is MariMed stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 29.63% in 2025-2026.
We have gathered data from 1 analysts. Their low revenue estimate is $171.46M, average is $178.1M and high is $184.73M.
What is MariMed stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 161.33% in 2025-2026.
We have gathered data from 1 analysts. Their low earnings per share estimate is $0.01, average is $0.01 and high is $0.01.
What is the best performing analyst?
In the last twelve months analysts have been covering MariMed stock. The most successful analyst is Kyle Bauser.